Get the Stockscreener App
3.55
10.58%
-0.42
Pre-market:
3.60
0.05
+1.41%
X 4 Pharmaceuticals Inc stock is traded at $3.55, with a volume of 631.01K.
It is down -10.58% in the last 24 hours and up +2.01% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.97
Open:
$3.72
24h Volume:
631.01K
Relative Volume:
0.16
Market Cap:
$79.70M
Revenue:
$32.77M
Net Income/Loss:
$-101.98M
P/E Ratio:
-0.3694
EPS:
-9.6101
Net Cash Flow:
$-112.43M
1W Performance:
-5.08%
1M Performance:
+2.01%
6M Performance:
+7.58%
1Y Performance:
-78.72%
1-Day Range:
$3.5475
$3.90
1-Week Range:
$3.5475
$4.15
52-Week Range:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.55 | 314.48M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.00 | 107.10B | 11.70B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
644.19 | 66.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.56 | 55.95B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
832.35 | 51.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.88 | 38.98B | 447.02M | -1.18B | -906.14M | -6.1812 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference - MarketScreener
X4 Pharmaceuticals Cuts Losses And Wins Wall Street’s Praise - Finimize
Wall Street analysts’ outlook for X4 Pharmaceuticals Inc (XFOR) - setenews.com
X4 Pharmaceuticals, Inc SEC 10-Q Report - TradingView
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
X4 Pharma Q3 net loss narrows to $29.8 mln - MarketScreener
X4 Pharmaceuticals: Q3 Earnings Snapshot - king5.com
X4 Pharmaceuticals (NASDAQ: XFOR) extends cash runway to 2028 after $240.3M financings - Stock Titan
How to build a dashboard for X4 Pharmaceuticals Inc. stockWall Street Watch & Weekly Top Gainers Trade List - newser.com
Using economic indicators to assess X4 Pharmaceuticals Inc. potentialQuarterly Earnings Report & Entry and Exit Point Strategies - newser.com
Is X4 Pharmaceuticals Inc. (48Q0) stock a fit for income portfoliosBear Alert & Daily Market Momentum Tracking - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from AI adoptionTrade Analysis Report & Momentum Based Trading Ideas - newser.com
Top chart patterns to watch in X4 Pharmaceuticals Inc.Portfolio Return Report & Precise Trade Entry Recommendations - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from commodity pricesEarnings Growth Report & Trade Opportunity Analysis Reports - newser.com
How strong is X4 Pharmaceuticals Inc. stock revenue growthInflation Watch & Expert Approved Trade Ideas - newser.com
Combining machine learning predictions for X4 Pharmaceuticals Inc.Quarterly Earnings Summary & Verified Stock Trade Ideas - newser.com
What moving averages say about X4 Pharmaceuticals Inc.CPI Data & Advanced Technical Analysis Signals - newser.com
Why X4 Pharmaceuticals Inc. stock could benefit from AI revolutionWeekly Market Summary & Reliable Intraday Trade Alerts - newser.com
Will X4 Pharmaceuticals Inc. stock recover after recent dropPrice Action & Advanced Swing Trade Entry Plans - newser.com
What recovery options are there for X4 Pharmaceuticals Inc.Quarterly Earnings Summary & Community Supported Trade Ideas - newser.com
Can volume confirm reversal in X4 Pharmaceuticals Inc.Trade Signal Summary & AI Forecasted Entry/Exit Points - newser.com
How dovish Fed policy supports X4 Pharmaceuticals Inc. (48Q0) stockPortfolio Profit Report & Technical Entry and Exit Alerts - newser.com
X4 Pharmaceuticals Inc 48Q0 Stock Analysis and ForecastTechnical Breakout Signals & Double Digit Wealth Tips - earlytimes.in
Published on: 2025-10-28 05:23:25 - newser.com
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million - The Manila Times
X4 Pharmaceuticals Completes $155.3 Million Public Offering of Common Stock - Quiver Quantitative
X4 Pharma (NASDAQ: XFOR) closes $155.3M offering; underwriters' option fully exercised - Stock Titan
Craig Adam R buys x4 pharmaceuticals shares for $249,997 - Investing.com India
Why X4 Pharmaceuticals Inc. stock appeals to dividend seekers2025 Technical Overview & Consistent Profit Alerts - fcp.pa.gov.br
Why X4 Pharmaceuticals Inc. stock is a value investor pickJuly 2025 Gainers & Long Hold Capital Preservation Plans - Fundação Cultural do Pará
X4 Pharmaceuticals announces $145.6 million public offering of common stock - Investing.com
What candlestick patterns are forming on X4 Pharmaceuticals Inc.Earnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
X4 Pharmaceuticals Bolsters Financial Stability Amid Strategic Development - StocksToTrade
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.82%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):